CARR EDWARD (CIK 1273351) reported 14 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-18). Recent activity: Buy DNTH (20,000 shares), Sell DNTH (7,928 shares), Sell DNTH (6,771 shares), Sell DNTH (3,501 shares), Sell DNTH (1,100 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Buy | 20,000 | $357,600 |
| 2026-09-18 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 7,928 | $796,209 |
| 2026-09-18 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 6,771 | $686,376 |
| 2026-09-18 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 3,501 | $358,467 |
| 2026-09-18 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 1,100 | $113,520 |
| 2026-09-18 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 700 | $73,073 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Buy | 16,182 | $289,334 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Buy | 17,500 | $386,225 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Buy | 10,000 | $217,700 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 15,852 | $1.3M |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 23,465 | $1.9M |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 3,865 | $319,481 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 200 | $16,676 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | CHIEF ACCOUNTING OFFICER | Sell | 300 | $25,659 |
来源：SEC Form 4 申报文件 · 截至 2026-09-18